|
**Overview**: **TBNK COVID Severity Profile****Introduction**: The TBNK COVID Severity Profile is a diagnostic tool designed to assess COVID-19 severity using whole blood samples. Associated with conditions like severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, these disorders present with fever, shortness of breath, and severe complications if untreated, particularly in individuals with suspected COVID-19. Per the 2023 Hematology guidelines, the test employs hematology with flow cytometry technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for COVID-19 evaluation in clinical settings. This diagnostic falls under COVID-19 evaluation and targets individuals with confirmed or suspected COVID-19, addressing the challenge of accurate immune cell assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its blood-based approach ensures reliable detection.**Other Names**: TBNK COVID Pfl.**FDA Status**: FDA approved, CLIA certified for hematology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 2020s by immunology labs, this test advanced COVID-19 severity assessment.**Purpose**: The test screens for 12 parameters including CD3 to guide COVID-19 severity assessment, assess immune cell populations, and inform treatment and prevention strategies.**Test Parameters**: 1. CD3, 2. CD4, 3. CD8, 4. CD19, 5. CD56, 6. Absolute CD3 Count, 7. Absolute CD4 Count, 8. Absolute CD8 Count, 9. Absolute CD19 Count, 10. Absolute CD56 Count, 11. CD4/CD8 Ratio, 12. Total Lymphocyte Count.**Pretest Condition**: No fasting required; patients should report fever, shortness of breath, or recent COVID-19 symptoms.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not specified, immediate processing recommended to preserve cell integrity.**Medical History**: Patients should provide details on fever, shortness of breath, prior COVID-19 reactions, or family history of respiratory infections, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated COVID-19 including respiratory failure, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using flow cytometry and interpret results within 1-2 days using provided controls.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent immunosuppressive therapy can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible severe COVID-19, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist.**Specialist Consultation**: General practitioners or specialists in infectious disease should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: Chest CT or PCR for confirmation.**Test Limitations**: The test may produce false negatives in early infection stages or false positives in sample degradation, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: Hematology Guidelines 2023, Journal of Infectious Diseases 2024, Biochemistry 2025. |
